Beta-thalassemia major is the prototypical indication for chronic iron chelation. Lifelong red-cell transfusions deliver large iron loads, while ineffective erythropoiesis simultaneously increases gastrointestinal iron absorption. Without effective chelation, iron deposition drives cardiomyopathy, hepatic fibrosis and endocrine failure - historically the leading causes of mortality in untreated patients.
Disease Background #
Thalassemias are inherited disorders of hemoglobin synthesis. Beta-thalassemia major presents in the first year of life with severe anemia and requires regular transfusions (typically every 2-4 weeks) to maintain growth and quality of life. Beta-thalassemia intermedia includes a spectrum of milder phenotypes - some patients still develop iron overload through increased intestinal absorption (non-transfusional iron overload, NTDT), even without regular transfusion.
Why Iron Overload Develops #
- Each unit of packed red cells delivers ~200 mg elemental iron.
- A child receiving 12-17 transfusions per year accumulates 5-10 g/year of iron.
- Ineffective erythropoiesis suppresses hepcidin, increasing intestinal iron absorption.
- The body has no regulated iron-excretion mechanism - chelation is the only effective intervention.
Role of Deferasirox #
Deferasirox is a once-daily oral chelator that has become the standard of care for transfusional iron overload in beta-thalassemia. The dispersible tablet format supports accurate weight-based dosing in pediatric patients - typically initiated around 20 mg/kg/day and titrated by 5-10 mg/kg/day every 3-6 months based on serum ferritin, LIC and tolerability.
Monitoring in Thalassemia #
| Monitoring | Frequency |
|---|---|
| Serum ferritin | Monthly |
| Renal function (creatinine, CrCl) | Weekly during initiation, then monthly |
| Liver function tests | Monthly |
| LIC by MRI R2 / T2* | Every 6-12 months |
| Cardiac T2* | Annually from age 8-10 years |
| Endocrine screening | Annually (growth, puberty, thyroid, glycaemia) |
| Audiology / ophthalmology | Annually |
Non-Transfusion-Dependent Thalassemia (NTDT) #
In NTDT, iron overload is driven primarily by increased absorption rather than transfusion. Deferasirox is approved for NTDT iron overload in many markets from age 6 years, typically at lower doses (e.g. 5-10 mg/kg/day starting). The treatment goal is to keep LIC below 5 mg Fe/g dry weight.
Long-Term Outcomes #
With sustained chelation, modern thalassemia patients have substantially improved survival, preserved cardiac function and reduced endocrine complications compared with the pre-chelation era. Adherence is the single most important predictor of long-term outcome - which is why the convenience of once-daily oral therapy with DEFRATAJ matters clinically.